glp-1 gastrointestinal obstruction class action in kentucky legal team Zepbound Lawsuit [2026] Patients Are Suing Over Alleged

receives research funding from Boehringer Ingelheim

The STEP-HFpEF-DM trial confirmed the benefits of once-weekly semaglutide also in obese patients affected by type 2 diabetes

Zaccardi F, Jacquot E, Cortese V, et al

Users who have switched between GLP-1 medications often report changes in side effect severity that may warrant adjusting their supplement protocol

Management of lifestyle factors The newest guidelines from the American Diabetes Association and Kidney Disease Improving Global Outcomes (KDIGO) highlight the role of patient education in nutritional management from dietitians for optimal diabetes management